Tumor‐infiltrating Tregs have the potential to hinder effector T cell function through various mechanisms, including the release of suppressive cytokines like IL‐10, IL‐35, and TGF‐β, as well as the expression of immunoinhibitory surface molecules such as CD39, CD73, and CTLA‐4.[28, 43] This characteristic may elucidate the mechanism behind the decreased infiltration of CD8+ T cells and their dysfunction resulting from Gal1. Here, ENTPD1 is linked to neoplasm.